SANTA MONICA, Calif., March 6, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that David Chang, M.D., Ph.D., Kite's Executive Vice President, Research and Development, and Chief Medical Officer, will present a company overview at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel. The presentation will take place on Tuesday March 10, 2015, at 9:30 a.m. EDT.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com.
CONTACT: Kite Contacts:
Cynthia M. Butitta
Chief Financial Officer and Chief Operating Officer
(310) 824-9999
For Media: Justin Jackson
For Investor Inquiries: Nancy YuBurns McClellan
(212) 213-0006
jjackson@burnsmc.comnyu@burnsmc.comKite Pharma, Inc.News Provided by Acquire Media
